Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 4.97K
+0.60%-2.64%+20.82%+10.64% 216B
-1.51%-3.79%-4.51%-20.62% 142B
+0.22%-2.50%-18.72%+36.80% 138B
-1.87%-1.41%-51.02%+0.56% 74.53B
+0.19%-2.86%+16.19%+18.80% 52.34B
+1.18%+0.74%-16.17%-14.38% 50.28B
-0.01%-0.70%+25.64%+24.48% 41.93B
-1.59%-3.31%+38.65%+48.61% 40.06B
+0.36%-0.16%-0.74%+6.25% 32.69B
Average -0.08%-0.52%+1.13%+12.35% 87.63B
Weighted average by Cap. +0.00%-1.16%+0.14%+10.05%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
7
  1. Stock Market
  2. Stocks
  3. SCIE Stock